
Validea's guru fundamental report indicates that Gilead Sciences Inc. (GILD) receives a 100% rating based on their Twin Momentum Investor model, which is based on the strategy of Dashan Huang. The model combines fundamental momentum, using seven fundamental variables, with price momentum, and has historically shown that stocks in the top 20% of the universe according to that measure outperformed the market going forward; combining that measure with price momentum doubled its outperformance.
Gilead Sciences Inc. (GILD) has received a maximum 100% rating from Validea's Twin Momentum Investor model, a strategy developed by Dashan Huang that integrates both fundamental momentum and price momentum. This model identifies stocks with improving fundamentals—specifically analyzing seven variables including earnings, return on equity, return on assets, accrual operating profitability to equity, cash operating profitability to assets, gross profit to assets, and net payout ratio—and strong price trends. GILD, a large-cap growth stock in the Biotechnology & Drugs sector, successfully passed all criteria within this model, including specific tests for 'Fundamental Momentum' and 'Twelve Minus One Momentum', culminating in a 'Pass' for its 'Final Rank'. A score exceeding 90% from this Validea strategy typically signifies strong interest, positioning GILD favorably under this quantitative assessment. The underlying academic research by Dashan Huang indicated that stocks ranking in the top 20% for fundamental momentum historically outperformed the market, with this outperformance doubling when combined with price momentum, lending further weight to GILD's perfect score.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment